Transforming growth factorbeta(1) transactivates EGFR via an H(2)O(2)-dependent mechanism in squamous carcinoma cell line

Cancer Lett. 2010 Apr 1;290(1):43-8. doi: 10.1016/j.canlet.2009.08.022. Epub 2009 Sep 13.

Abstract

TGFbeta is known to transactivate EGFR. However, the signaling component involved in this crosstalk has yet to be revealed. Here, we found that TGFbeta(1) phosphorylated EGFR in a dose-dependent manner in SCC13 and A431 cells, and it was not blocked by EGF-neutralizing antibody. H(2)O(2) was increased by TGFbeta(1) treatment in the same time-kinetics as EGFR activation. Pretreatment of N-acetyl cysteine abolished TGFbeta(1)-induced H(2)O(2) induction and EGFR activation. Direct treatment of H(2)O(2) phosphorylated EGFR and catalase inhibitor prolonged TGFbeta(1)-induced EGFR activation. These results show that TGFbeta(1) activates EGFR via an H(2)O(2)-dependent mechanism, which subsequently leads to the activation of Erk(1/2).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Squamous Cell / genetics
  • Carcinoma, Squamous Cell / metabolism*
  • Cell Line, Tumor
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism*
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Hydrogen Peroxide / metabolism*
  • Immunoblotting
  • Immunoprecipitation
  • Phosphorylation
  • Reactive Oxygen Species / metabolism
  • Receptor Cross-Talk
  • Signal Transduction / physiology*
  • Transcriptional Activation
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism*

Substances

  • Reactive Oxygen Species
  • Transforming Growth Factor beta1
  • Hydrogen Peroxide
  • ErbB Receptors
  • Extracellular Signal-Regulated MAP Kinases